Repligen (NASDAQ:RGEN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Repligen (NASDAQ:RGEN) from a hold rating to a buy rating in a research report sent to investors on Saturday.

A number of other research analysts have also commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $180.00 price target on shares of Repligen in a research report on Monday, May 5th. JPMorgan Chase & Co. decreased their target price on Repligen from $200.00 to $190.00 and set an “overweight” rating for the company in a report on Tuesday, April 29th. Canaccord Genuity Group decreased their price objective on shares of Repligen from $170.00 to $150.00 and set a “hold” rating for the company in a report on Wednesday, April 16th. Wolfe Research upgraded shares of Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price objective for the company in a report on Tuesday, April 29th. Finally, Royal Bank Of Canada decreased their price objective on shares of Repligen from $202.00 to $189.00 and set an “outperform” rating for the company in a report on Wednesday, April 30th. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, Repligen has a consensus rating of “Moderate Buy” and a consensus target price of $173.25.

Repligen Stock Performance

Shares of RGEN stock opened at $120.11 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. Repligen has a fifty-two week low of $102.97 and a fifty-two week high of $182.52. The stock has a 50 day moving average price of $128.57 and a two-hundred day moving average price of $141.68. The company has a market capitalization of $6.75 billion, a P/E ratio of -266.91, a PEG ratio of 3.40 and a beta of 1.11.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating analysts’ consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The company had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. During the same period in the prior year, the business posted $0.28 EPS. The firm’s revenue was up 10.4% compared to the same quarter last year. Analysts expect that Repligen will post 1.72 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD increased its holdings in shares of Repligen by 11.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock valued at $1,027,165,000 after acquiring an additional 743,815 shares in the last quarter. Point72 Asset Management L.P. increased its stake in Repligen by 183.1% during the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company’s stock valued at $132,227,000 after purchasing an additional 594,189 shares in the last quarter. Groupama Asset Managment increased its stake in Repligen by 12,321.0% during the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company’s stock valued at $58,142,000 after purchasing an additional 400,680 shares in the last quarter. Alyeska Investment Group L.P. bought a new stake in Repligen during the 4th quarter valued at about $53,428,000. Finally, Raymond James Financial Inc. bought a new stake in Repligen during the 4th quarter valued at about $52,492,000. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.